Bright Peak Therapeutics Presents New Data at the 2024 Ameri

Bright Peak Therapeutics Presents New Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
BPT567, a first-in-class PD1-IL18 immunoconjugate designed to enable cis-signaling and preferentially activate intratumoral PD1+IL18R+ effector T cells induces potent preclinical antitumor activity

GlobeNewswire

April 09, 2024



SAN DIEGO and BASEL, Switzerland, April 09, 2024 (GLOBE...

Related Keywords

United States , Switzerland , San Diego , California , American , Jon Wigginton , Development Of Bright Peak Therapeutics , American Association For Cancer Research , Bright Peak Therapeutics Presents New Data , Cancer Research , Peak Therapeutics , American Association , Annual Meeting , Bright Peak , Abstract Highlights , Bright Peak Therapeutics , Del Mar ,